PAST EVENT - Boston-PBSS In-Person Workshop on Preclinical Development and IND Filing

Boston skyline at dusk with Cambridge in view across the Charles River

Thank you for joining Pharmaron at the Boston-PBSS In-Person Workshop on Preclinical Development and IND Filing.

Pharmaron was proud to sponsor the Boston Pharmaceutical & BioScience Society (Boston-PBSS) In-Person Workshop on Preclinical Development and IND Filing for New Modalities, ADCs, SiRNA/ASO, Gene and Cell Therapies: Nuts, Bolts, Best Practices, and Regulatory Requirements. This event occurred on November 6th, 2024, from 8:15 AM to 5:10 PM ET at the Marriott Cambridge, 50 Broadway, Cambridge, MA 02142.

This workshop was a fantastic opportunity to gain insights into the latest preclinical development and advancements in regulatory requirements. Whether you’re working on Antibody-Drug Conjugates (ADCs), siRNA/ASO, or Gene and Cell Therapies, this event provided critical knowledge and best practices to ensure your projects progress smoothly toward IND filings.

If you missed our table at the event or meeting our team to discuss how Pharmaron’s comprehensive services can support your upcoming projects, from discovery through clinical development, you can still request a meeting below. Our experts are ready to explore how we can help you navigate the complex regulatory landscape and efficiently bring your therapeutic candidates to market.

Special Talk by Rafiq Islam

Our Vice President of Bioanalysis and Biomarker, Rafiq Islam, delivered a talk from 10:25 to 10:35 on Comprehensive Immunogenicity Assessment for rAAV Gene Therapy: Regulatory Considerations for IND Submissions. If you missed this insightful session, Rafiq is happy to meet with you to discuss best practices and regulatory requirements for advancing gene therapies through the IND process.

Speaker
Rafiq Islam
Vice President
Bioanalysis and Biomarker

Boston Pharmaceutical & BioScience Society (Boston-PBSS) Workshop – “Preclinical Development and IND Filing for New Modalities, ADCs, SiRNA/ASO, Gene and Cell Therapies: Nuts, Bolts, Best Practices, and Regulatory Requirements”

The development of new therapeutic modalities—such as antibody-drug conjugates (ADCs), SiRNA/ASO, and gene and cell therapies—has surged in recent years. Filing an Investigational New Drug (IND) application is critical in bringing these therapies to market. While the basics of IND filings are consistent across modalities, specific considerations are crucial for ADCs, SiRNA/ASO, and gene and cell therapies. This workshop will provide insights into best practices for crafting a successful IND package and is ideal for both new developers and those experienced in small molecule development.


For more information and event registration, please visit Boston-PBSS Workshop.

Request a Meeting